S Z Pavletic

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
    Steven Z Pavletic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room CRC 3 3330, Bethesda, MD 20892 1907, USA
    J Clin Oncol 23:5788-94. 2005
  2. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 1
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 11:862-70. 2005
  3. doi request reprint Are we making progress in GVHD prophylaxis and treatment?
    Steven Z Pavletic
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Hematology Am Soc Hematol Educ Program 2012:251-64. 2012
  4. ncbi request reprint Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Hematol 78:265-74. 2005
  5. ncbi request reprint Genetically identical twin transplantation for chronic lymphocytic leukemia
    S Z Pavletic
    National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Leukemia 21:2452-5. 2007
  6. ncbi request reprint Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
  7. pmc Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation
    Steven Z Pavletic
    University of Nebraska Medical Center, Omaha, USA
    Blood 106:3308-13. 2005
  8. ncbi request reprint Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials
    S Z Pavletic
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Bone Marrow Transplant 38:645-51. 2006
  9. ncbi request reprint Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Transplantation 76:877-81. 2003
  10. ncbi request reprint Oral chronic graft-vs.-host disease characterization using the NIH scale
    H Fassil
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Dent Res 91:45S-51S. 2012

Detail Information

Publications63

  1. ncbi request reprint Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
    Steven Z Pavletic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room CRC 3 3330, Bethesda, MD 20892 1907, USA
    J Clin Oncol 23:5788-94. 2005
    ..To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL)...
  2. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 1
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 11:862-70. 2005
  3. doi request reprint Are we making progress in GVHD prophylaxis and treatment?
    Steven Z Pavletic
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Hematology Am Soc Hematol Educ Program 2012:251-64. 2012
    ....
  4. ncbi request reprint Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Hematol 78:265-74. 2005
    ..More studies are needed to determine whether cGVHD prognostic systems should be used interchangeably in patient populations receiving different stem-cell products...
  5. ncbi request reprint Genetically identical twin transplantation for chronic lymphocytic leukemia
    S Z Pavletic
    National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Leukemia 21:2452-5. 2007
    ..The case of leukemia transfer indicates the need for careful evaluation of donors prior to graft collection...
  6. ncbi request reprint Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
  7. pmc Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation
    Steven Z Pavletic
    University of Nebraska Medical Center, Omaha, USA
    Blood 106:3308-13. 2005
    ..In spite of a significant reduction of acute GVHD, TCD did not reduce the incidence of cGVHD or improve survival in patients who developed cGVHD...
  8. ncbi request reprint Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials
    S Z Pavletic
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Bone Marrow Transplant 38:645-51. 2006
    ..The ultimate success of this project is dependent on whether these recommendations move the field forward. This is an opportunity for the transplant community to unite and make a significant impact in chronic GVHD...
  9. ncbi request reprint Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Transplantation 76:877-81. 2003
    ..5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT...
  10. ncbi request reprint Oral chronic graft-vs.-host disease characterization using the NIH scale
    H Fassil
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Dent Res 91:45S-51S. 2012
    ..We propose the use of >2 points on the NIH scale as a reproducible definition of clinically significant oral cGVHD, which may be useful in clinical settings or as eligibility criterion or as an endpoint in clinical trials...
  11. pmc Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research
    J W Mays
    Clinical Research Core, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892 4320, USA
    Oral Dis 19:327-46. 2013
    ....
  12. doi request reprint Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures
    C W Bassim
    National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
    Bone Marrow Transplant 49:116-21. 2014
    ..This study supports the use of the NIH OMS and its components (erythema, lichenoid and ulcerations) to measure clinician-reported severity of oral cGVHD. ..
  13. ncbi request reprint Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis
    S Z Pavletic
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198 7680, USA
    J Rheumatol Suppl 64:28-31. 2001
    ..Future ASCT strategies need to focus on improving the durability of the early posttransplant responses...
  14. ncbi request reprint Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: the University of Nebraska experience
    S Z Pavletic
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198 7680 USA
    J Rheumatol Suppl 64:13-20. 2001
    ..The second patient progressed relentlessly 15 months post-transplant. Immunological reconstitution showed a continuous inversion of the ratio of CD4 and CD8 lymphocytes with a predominant expansion of memory T cells...
  15. pmc Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity
    L Grkovic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leukemia 26:633-43. 2012
    ..0001) were associated with more severe diseased defined by NIH global score. This study identified common laboratory indicators of inflammation that can serve as markers of cGVHD activity and severity...
  16. ncbi request reprint Chronic graft-versus-host disease in the era of reduced-intensity conditioning
    D S Subramaniam
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leukemia 21:853-9. 2007
    ..The recent National Institutes of Health chronic GVHD consensus project recommendations provide now the critically needed standardized guidelines for the diagnosis, classification and staging of chronic GVHD...
  17. ncbi request reprint Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations
    T R McGuire
    Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE, USA
    Bone Marrow Transplant 28:889-93. 2001
    ..75 times more likely to develop OD (95% CI = 1.3-5.8; P = 0.0087). The early elevation of IL-6 in patients who develop OD may help identify a high risk group where preventive therapies can be evaluated...
  18. doi request reprint Active thrombopoiesis is associated with worse severity and activity of chronic GVHD
    T Bat
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Bone Marrow Transplant 48:1569-73. 2013
    ..Among patients with stable moderate or severe cGVHD, there was no evidence of hypoproduction of platelets. Future studies should further investigate the role of thrombopoiesis in cGVHD. ..
  19. ncbi request reprint Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease
    M R Robinson
    National Eye Institute NIH, 10 10S229, 110 Center Drive, MSC 1863, Bethesda, MD 20892 1863, USA
    Bone Marrow Transplant 33:1031-5. 2004
    ..Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial...
  20. ncbi request reprint Chronic graft versus host disease of oral mucosa: review of available therapies
    Matin M Imanguli
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:175-83. 2006
    ..Available evidence for efficacy and safety of various systemic and topical agents, including corticosteroids, calcineurin antagonists, mycophenolate mofetil, and extracorporeal photopheresis, is reviewed...
  21. doi request reprint Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease
    Jane M Fall-Dickson
    National Institute of Nursing Research, Bethesda, MD, USA
    Biol Blood Marrow Transplant 16:948-56. 2010
    ..The positive associations between IL-6 and oral cGVHD severity and erythema, as well as the positive trend with oral ulceration, warrant further exploration of this cytokine as a potential biomarker of active oral cGVHD...
  22. doi request reprint Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, CRC Room 4 3152, Bethesda, MD 20892, USA
    Cancer 116:852-62. 2010
    ....
  23. ncbi request reprint Chronic graft versus host disease
    Kristin Baird
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Curr Opin Hematol 13:426-35. 2006
    ..The purpose of this review is to overview this disease and highlight recent findings in the literature over the past year...
  24. pmc Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa
    Matin M Imanguli
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 113:3620-30. 2009
    ..The clinical trials are registered at http://www.clinicaltrials.gov as NCT00331968...
  25. doi request reprint Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation
    Kirsten M Williams
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bldg 10 CRC, Room 3 3288, 10 Center Dr, Bethesda, MD 20892, USA
    JAMA 302:306-14. 2009
    ..Improvements in survival will likely require early disease recognition, allowing for therapeutic modulation of disease prior to the development of irreversible airway obliteration...
  26. ncbi request reprint Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:22-30. 2006
    ..The contrasting change in central memory cells (CD8(+) increased versus CD4(+) decreased) in cGVHD provide support for recent reports suggesting unique differences in the differentiation pathways for CD8(+) versus CD4(+) T cells...
  27. pmc Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation
    Matin M Imanguli
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 16:1362-9. 2010
    ..Formal evaluation of salivary function using standardized criteria is needed, and this could be incorporated as an outcome measure in clinical trials of cGVHD...
  28. doi request reprint Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease
    Nikolay P Nikolov
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch of the National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
    Nat Clin Pract Rheumatol 4:184-91. 2008
    ..HSC transplantation is associated with inherent morbidity and mortality, both treatment-related and disease-related, and selecting the correct group of patients with the best risk:benefit ratio is a challenging task...
  29. doi request reprint Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?
    Rachel B Salit
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Curr Hematol Malig Rep 5:229-38. 2010
    ....
  30. ncbi request reprint Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
    ..This finding implies that overrepresentation of CD4(EM) cells is a unique feature of cGVHD...
  31. ncbi request reprint Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 126:837-43. 2004
    ..Targeted lymphocyte depletion may permit an individualized approach to conditioning based on host immune status prior to RIST...
  32. pmc Acupuncture treatment for persistent hiccups in patients with cancer
    Adeline X Y Ge
    Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    J Altern Complement Med 16:811-6. 2010
    ..The objective of this study was to investigate the effects of acupuncture treatment for persistent hiccups in cancer patients...
  33. ncbi request reprint Blood stem cells as therapy for severe lupus
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, Sjögren s Syndrome Clinic, 9000 Rockville Pike, Bethesda, MD 20892 1190, USA
    Expert Opin Biol Ther 5:1153-64. 2005
    ..All immunoablative protocols should incorporate studies of immune reconstitution to understand the mechanisms of cure or failure...
  34. pmc National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 17:443-54. 2011
    ..These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT...
  35. ncbi request reprint Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease
    I Pusic
    University of Nebraska Medical Center, Department of Internal Medicine, Section of Oncology and Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Bone Marrow Transplant 29:709-10. 2002
    ..A total of 4.03 x 10(6)/kg CD34+ cells were infused and hematological recovery was rapid. Chronic GVHD improved with the ability to taper steroids. Nine months post transplantation the patient died from leukemia...
  36. pmc Oral graft-versus-host disease
    M M Imanguli
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Oral Dis 14:396-412. 2008
    ..This review describes the oral component of this transplant complication...
  37. ncbi request reprint Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics
    S S Joshi
    Department of Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, USA
    Blood 98:1963-70. 2001
    ..These results suggest a decreased immune function in G-CSF-mobilized BSC harvests and warrant further studies to correlate these data with clinical outcome...
  38. ncbi request reprint The role of immune ablation and stem cell transplantation in severe SLE
    Steven Z Pavletic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Autoimmunity Branch, National Cancer Institute, Bethesda, MD, USA
    Best Pract Res Clin Rheumatol 19:839-58. 2005
    ..All immunoablative protocols should incorporate carefully planned studies of immune reconstitution to understand the mechanisms of cure or failure...
  39. pmc Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
    M R Bishop
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Ann Oncol 19:1935-40. 2008
    ..The analysis was restricted to patients with DLBCL, who were either not in complete remission at day +100 after allogeneic stem-cell transplantation or subsequently relapsed beyond this time point...
  40. pmc Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)
    S A Mitchell
    Nursing Research, Clinical Center, National Institutes of Health, Bethesda, MD 20852, USA
    Bone Marrow Transplant 45:762-9. 2010
    ..004). Results suggest two possible mechanisms underlying impaired functional performance in survivors with cGVHD and underscore the importance of testing interventions to enhance functional capacity and reduce symptom bother...
  41. doi request reprint Thrombocytopenia and hemostatic disorders in chronic graft versus host disease
    D Pulanic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
    Bone Marrow Transplant 44:393-403. 2009
    ..Future clinical trials with agents that stimulate megakaryocytopoiesis or influence underlying impaired hemostasis mechanisms should investigate whether such interventions may improve outcomes in patients with cGVHD...
  42. pmc A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Blood 114:4494-502. 2009
    ..Trials described herein were registered at www.clinicaltrials.gov as nos. NCT00055744 and NCT00003838...
  43. pmc Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation
    Brian A Harris
    Pain and Palliative Care Service, National Institutes of Health Clinical Center, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Support Oncol 8:119-25. 2010
    ..Research is needed to identify factors that diminish Sp-WB and to test interventions designed to strengthen this coping resource in patients experiencing the late effects of treatment...
  44. doi request reprint Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease
    Jason Clark
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Arch Dermatol 145:918-22. 2009
    ....
  45. ncbi request reprint High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation
    Timothy R McGuire
    Department of Pharmacy Practice, University of Nebraska Medical Center, 986045, Omaha, NE 68198 6045, USA
    Int Immunopharmacol 3:279-83. 2003
    ..In conclusion, in this small case series, there was no indication that CTX metabolism was different than that in other populations undergoing transplantation...
  46. pmc Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation
    Matin M Imanguli
    Clinical Research Core, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 35:184-92. 2007
    ..This study was an initial evaluation of salivary protein changes that occur after allo-HCT...
  47. pmc Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients
    Asha R Patel
    Dermatology Branch, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 15:370-6. 2009
    ..A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGVHD...
  48. pmc Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 14:379-84. 2008
  49. ncbi request reprint Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation
    Kathleen M Healey
    Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
    Mult Scler 10:284-9. 2004
    ..The results demonstrate however, a dissociation of inflammation parameters and functional disability findings raising questions about optimal future stem cell transplantation strategies for this disease...
  50. ncbi request reprint Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma
    Marin Nola
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Hematol 77:31-5. 2004
    ..In multivariate analysis, the IPI score was the only significant predictor of OS. Anemia and B symptoms were additionally predictive of poor OS in patients with low IPI scores...
  51. ncbi request reprint Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
    Patricia Aoun
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Leuk Lymphoma 45:1595-603. 2004
    ..Interphase FISH studies improve the cytogenetic diagnosis when performed in conjunction with karyotyping in B-CLL/SLL, but the prognostic relevance of various abnormalities could not be confirmed in this study...
  52. ncbi request reprint Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report
    Kirk R Schultz
    British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 12:126-37. 2006
    ..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
  53. ncbi request reprint Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
    Gorgun Akpek
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 102:802-9. 2003
    ..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed...
  54. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
    ..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...
  55. ncbi request reprint Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic an
    Linda M Griffith
    Biol Blood Marrow Transplant 12:688-90. 2006
  56. ncbi request reprint Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease
    Christopher N Bredeson
    Center for International Blood and Marrow Transplant Research, Health Policy Institute, Medical College of Wisconsin, Milwaukee 53226, USA
    Best Pract Res Clin Haematol 17:327-43. 2004
    ..Although no blueprint for designing and conducting a trial of HSCT for autoimmune diseases can be laid out, the process should take into consideration the issues highlighted herein...
  57. ncbi request reprint Transplantation's greatest challenges: advances in chronic graft-versus-host disease
    Warren D Shlomchik
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Blood Marrow Transplant 13:2-10. 2007
    ..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
  58. ncbi request reprint CD34-selected versus unmanipulated grafts for severe rheumatoid arthritis: comment on the article by Moore et al
    Jacob M van Laar
    Arthritis Rheum 48:1463-4; author reply 1464-6. 2003
  59. ncbi request reprint Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease
    Steven Z Pavletic
    Arthritis Rheum 50:2387-90. 2004
  60. ncbi request reprint National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  61. ncbi request reprint Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report
    Howard M Shulman
    Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:31-47. 2006
    ..Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies...
  62. pmc The isomorphic response in morphealike chronic graft-vs-host disease
    Asha R Patel
    Arch Dermatol 144:1229-31. 2008
  63. ncbi request reprint Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR
    John A Snowden
    Department of Rheumatology, Felix Platter Spital, University of Basel, Basel, Switzerland
    J Rheumatol 31:482-8. 2004
    ..To date, published reports have been individual cases or series containing small numbers. This study combined the worldwide experience in a single analysis...